STERIS plc’s stock price skyrockets to 246.88 USD, witnessing a substantial +8.52% surge

STERIS plc (STE)

246.88 USD +19.38 (+8.52%) Volume: 1.15M

STERIS plc’s stock price soars to $246.88, marking an impressive trading session increase of +8.52%, with a robust trading volume of 1.15M. The company’s stocks continue to outperform with a Year-to-Date percentage change of +20.10%, solidifying its strong market presence.

Latest developments on STERIS plc

STERIS (NYSE:STE) has been making waves in the stock market recently, with its stock price rising by 5.9% after beating Q4 2025 EPS forecasts. The company reported a 6% revenue growth and increased EPS for fiscal year 2025, leading to a positive outlook for fiscal 2026. Analysts have retained an overweight rating on STERIS stock with a price target of $250, indicating confidence in the company’s performance. STERIS’s strong financial performance in fiscal Q4 2025, particularly in the medical equipment sales sector, has led to a forecast of annual profit above estimates for the upcoming year. With revenue expectations surpassed and record earnings reported, STERIS is set to continue its growth trajectory with a projected 6-7% revenue growth for fiscal year 2026.

A look at STERIS plc Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on Smartkarma Smart Scores, STERIS has a positive long-term outlook with high scores in Growth and Momentum. The company operates in the healthcare industry, providing infection prevention products and services. With a strong momentum score of 5, STERIS is showing promising signs of growth and potential for future success.

Although STERIS scores lower in Value and Dividend, it still maintains a respectable overall outlook with a score of 3 in Resilience. This suggests that the company is able to withstand market fluctuations and challenges. Overall, STERIS’s focus on growth and momentum positions it well for long-term success in the healthcare, pharmaceutical, and medical device industries.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma